Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects
China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in…
Lacking Revenue, Lepu Biopharma Chases IPO to Revive War Chest
The cutting-edge cancer treatment company has not generated any revenue from its products, and only has enough money to last another three months Key takeaways: Lepu Biopharma has yet to…
PW Medtech’s Buying Spree: Diversification or Insider Story?
The manufacturer of medical infusion devices has recently made two interesting acquisitions Key takeaways: After buying a related peer in November, PW Medtech acquired a human tissue regeneration and repair…
RELATED ARTICLES
-
Manycore makes second listing attempt as mood brightens for tech companies
- Zhida looks for IPO charge as EV distress drains its coffers
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
- IPO tea party set to resume with Guming’s regulatory nod from China?
- Eternal Beauty struts its stuff as Hong Kong’s newest IPO contestant
- Shanghai Able’s renewed IPO plan hobbled by weak appetite for new tech listings
